Abstract
• IVI is a critical component of DCB angioplasty to ensure optimal lesion preparation for effective drug transfer and long-term patency. • DCB has demonstrated excellent outcomes in specific subset of lesions, like ISR (particularly ISR with homogeneous or layered neointima) and de novo small vessel disease, where it has often shown comparable or even superior results to DES. • In bifurcation lesions an approach of using DES in the main vessel and DCB for the side branch is highly effective, promoting positive remodelling and reducing adverse events. • DCB offers an attractive "leave no metal behind" option for high bleeding risk patients, allowing for abbreviated dual antiplatelet or single antiplatelet therapy.